In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
|Articles|July 20, 2012
Keith Dunleavy, MD, Speaks About Health and Data Research
Keith Dunleavy, MD, President and CEO, Inovalon, discusses the importance of comparative effectiveness research in order to improve chronic disease management at both the individual and population levels.
Advertisement
Keith Dunleavy, MD, President and CEO, Inovalon, discusses the importance of comparative effectiveness research in order to improve chronic disease management at both the individual and population levels. Dr. Dunleavy also addresses decision support through target interventions.
Advertisement
Related to this article
Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
3
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5